Suspected non-Alzheimer disease pathophysiology-concept and controversy

Nature Reviews Neurology

Volumn 12, Issue 2, 2016, Pages 117-124

  Jack, Clifford R ^a   Knopman, David S ^a   Chételat, Gaël ^b   Dickson, Dennis ^c   Fagan, Anne M ^d   Frisoni, Giovanni B ^e   Jagust, William ^f   Mormino, Elizabeth C ^g   Petersen, Ronald C ^a   Sperling, Reisa A ^g   Van Der Flier, Wiesje M ^h   Villemagne, Victor L ⁱ   Visser, Pieter J ^j   Vos, Stephanie J B ^j  

^a MAYO CLINIC   (United States)

^b UNIVERSITÉ DE CAEN   (France)

^c MAYO CLINIC   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF GENEVA   (Switzerland)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ AUSTIN HEALTH   (Australia)

^j MAASTRICHT UNIVERSITY   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLUORODEOXYGLUCOSE F 18; TAU PROTEIN; BIOLOGICAL MARKER;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; BRAIN METABOLISM; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; HUMAN; MEDIAL TEMPORAL LOBE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; REVIEW; BRAIN; COGNITION DISORDERS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

AGING; ALZHEIMER DISEASE; BIOMARKERS; BRAIN; COGNITION DISORDERS; HUMANS;

EID: 84957851743     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.251     Document Type: Review

References (152)

1. Griffith, J. W., Sokol, C. L., & Luster, A. D. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 32, 659-702 (2014).
2. Cardona, S. M., Garcia, J. A., & Cardona, A. E. The fine balance of chemokines during disease: trafficking, inflammation, and homeostasis. Methods Mol. Biol. 1013, 1-16 (2013).
3. Henrich, T. J., & Kuritzkes, D. R. HIV-1 entry inhibitors: recent development and clinical use. Curr. Opin. Virol. 3, 51-57 (2013).
4. Luther, S. A., & Cyster, J. G. Chemokines as regulators of T cell differentiation. Nat. Immunol. 2, 102-107 (2001).
5. Luster, A. D. The role of chemokines in linking innate and adaptive immunity. Curr. Opin. Immunol. 14, 129-135 (2002).
6. Nieto, M. et al. Roles of chemokines and receptor polarization in NK-Target cell interactions. J. Immunol. 161, 3330-3339 (1998).
7. Park, M. H. et al. Chemokines released from astrocytes promote chemokine receptor 5-mediated neuronal cell differentiation. Exp. Cell Res. 315, 2715-2726 (2009).
8. Shukaliak, J. A., & Dorovini-Zis, K. Expression of the β-chemokines RANTES and MIP-1β by human brain microvessel endothelial cells in primary culture. J. Neuropathol. Exp. Neurol. 59, 339-352 (2000).
9. Subileau, E. A. et al. Expression of chemokines and their receptors by human brain endothelium: implications for multiple sclerosis. J. Neuropathol. Exp. Neurol. 68, 227-240 (2009).
10. Ferguson, A. R., & Engelhard, V. H. CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors. J. Immunol. 184, 4079-4086 (2010).
11. Castellino, F. et al. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-Dendritic cell interaction. Nature 440, 890-895 (2006).
12. Hickman, H. D. et al. Chemokines control naive CD8+ T cell selection of optimal lymph node antigen presenting cells. J. Exp. Med. 208, 2511-2524 (2011).
13. Semmling, V. et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat. Immunol. 11, 313-320 (2010).
14. Hugues, S. et al. Dynamic imaging of chemokine-Dependent CD8+ T cell help for CD8+ T cell responses. Nat. Immunol. 8, 921-930 (2007).
15. Molon, B. et al. T cell costimulation by chemokine receptors. Nat. Immunol. 6, 465-471 (2005).
16. Camargo, J. F. et al. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J. Immunol. 182, 171-182 (2009).
17. Contento, R. L. et al. CXCR4-CCR5: a couple modulating T cell functions. Proc. Natl Acad. Sci. USA 105, 10101-10106 (2008).
18. Sheridan, B. S., & Lefrançois, L. Regional and mucosal memory T cells. Nat. Immunol. 12, 485-491 (2011).
19. Sallusto, F., Lenig, D., Mackay, C. R., & Lanzavecchia, A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187, 875-883 (1998).
20. Fukada, K., Sobao, Y., Tomiyama, H., Oka, S., & Takiguchi, M. Functional expression of the chemokine receptor CCR5 on virus epitope-specific memory and effector CD8+ T cells. J. Immunol. 168, 2225-2232 (2002).
21. Kohlmeier, J. E. et al. The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. Immunity 29, 101-113 (2008).
22. Weninger, W., Biro, M., & Jain, R. Leukocyte migration in the interstitial space of non-lymphoid organs. Nat. Rev. Immunol. 14, 232-246 (2014).
23. Ubogu, E. E., Callahan, M. K., Tucky, B. H., & Ransohoff, R. M. CCR5 expression on monocytes and T cells: modulation by transmigration across the blood-brain barrier in vitro. Cell. Immunol. 243, 19-29 (2006).
24. Quandt, J., & Dorovini-Zis, K. The β chemokines CCL4 and CCL5 enhance adhesion of specific CD4+ T cell subsets to human brain endothelial cells. J. Neuropathol. Exp. Neurol. 63, 350-362 (2004).
25. Kohlmeier, J. E. et al. Inflammatory chemokine receptors regulate CD8+ T cell contraction and memory generation following infection. J. Exp. Med. 208, 1621-1634 (2011).
26. Das, S. et al. Immune subversion by Mycobacterium tuberculosis through CCR5 mediated signaling: involvement of IL-10. PLoS ONE 9, e92477 (2014).
27. Kitade, H. et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes 61, 1680-1690 (2012).
28. Rossi, R. et al. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin. Exp. Immunol. 166, 184-190 (2011).
29. Chang, L. Y. et al. The indispensable role of CCR5 for in vivo suppressor function of tumor-Derived CD103+ effector/memory regulatory T cells. J. Immunol. 189, 567-574 (2012).
30. Dolan, M. J. et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat. Immunol. 8, 1324-1336 (2007).
31. Zhou, Y. et al. Impaired macrophage function and enhanced T cell-Dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J. Immunol. 160, 4018-4025 (1998).
32. Dragic, T. et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667-673 (1996).
33. Nguyêñ, G. T. et al. Phenotypic expressions of CCR5-?32/?32 homozygosity. J. Acquir. Immune Defic. Syndr. 22, 75-82 (1999).
34. Rottman, J. B. et al. Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am. J. Pathol. 151, 1341-1351 (1997).
35. Westmoreland, S. V. et al. Developmental expression patterns of CCR5 and CXCR4 in the rhesus macaque brain. J. Neuroimmunol. 122, 146-158 (2002).
36. Choi, D. Y., Lee, M. K., & Hong, J. T. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration. Neurobiol. Dis. 49, 159-168 (2013).
37. Klein, R. S. et al. Chemokine receptor expression and signaling in macaque and human fetal neurons and astrocytes: implications for the neuropathogenesis of AIDS. J. Immunol. 163, 1636-1646 (1999).
38. Meucci, O. et al. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc. Natl Acad. Sci. USA 95, 14500-14505 (1998).
39. Martinson, J. J., Chapman, N. H., Rees, D. C., Liu, Y. T., & Clegg, J. B. Global distribution of the CCR5 gene 32-basepair deletion. Nat. Genet. 16, 100-103 (1997).
40. Novembre, J., Galvani, A. P., & Slatkin, M. The geographic spread of the CCR5 ?32 HIV-resistance allele. PLoS Biol. 3, e339 (2005).
41. Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273, 1856-1862 (1996).
42. Ioannidis, J. P. et al. Effects of CCR5-?32, CCR2-64I, and SDF-1 3?A alleles on HIV-1 disease progression: an international meta-Analysis of individual-patient data. Ann. Intern. Med. 135, 782-795 (2001).
43. Walker, W. E. et al. Increased levels of macrophage inflammatory proteins result in resistance to R5-Tropic HIV-1 in a subset of elite controllers. J. Virol. 89, 5502-5514 (2015).
44. Baba, M. et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob. Agents Chemother. 49, 4584-4591 (2005).
45. Gulick, R. M. et al. Five-year safety evaluation of maraviroc in HIV-1-infected treatment-Experienced patients. J. Acquir. Immune Defic. Syndr. 65, 78-81 (2014).
46. Lazzarin, A. et al. The maraviroc expanded access program-safety and efficacy data from an open-label study. HIV Clin. Trials 16, 10-21 (2015).
47. Llibre, J. M. et al. Safety, efficacy and indications of prescription of maraviroc in clinical practice: factors associated with clinical outcomes. Antiviral Res. 120, 79-84 (2015).
48. Ftkenheuer, G. et al. Efficacy of short-Term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11, 1170-1172 (2005).
49. Gulick, R. M. et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359, 1429-1441 (2008).
50. Tan, Q. et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341, 1387-1390 (2013).
51. Dorr, P. et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721-4732 (2005).
52. Wilkin, T. J., Ribaudo, H. R., Tenorio, A. R., & Gulick, R. M. The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-Experienced HIV-infected patients. HIV Clin. Trials 11, 351-358 (2010).
53. Cuzin, L. et al. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study. J. Acquir. Immune Defic. Syndr. 61, 557-564 (2012).
54. Rossi, R. et al. Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc. J. Acquir. Immune Defic. Syndr. 54, e13-E14 (2010).
55. Arberas, H. et al. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function. J. Antimicrob. Chemother. 68, 577-586 (2013).
56. Funderburg, N. et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS ONE 5, e13188 (2010).
57. Romero-Snchez, M. C. et al. Effect of maraviroc on HIV disease progression-related biomarkers. Antimicrob. Agents Chemother. 56, 5858-5864 (2012).
58. Gutirrez, C. et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS ONE 6, e27864 (2011).
59. Pozo-Balado, M. M. et al. Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects. J. Infect. Dis. 210, 890-898 (2014).
60. Clifford, D. B., & Ances, B. M. HIV-Associated neurocognitive disorder. Lancet Infect. Dis. 13, 976-986 (2013).
61. Canestri, A. et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin. Infect. Dis. 50, 773-778 (2010).
62. Letendre, S. et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65, 65-70 (2008).
63. Letendre, S. Central nervous system complications in HIV disease: HIV-Associated neurocognitive disorder. Top. Antivir. Med. 19, 137-142 (2011).
64. Cysique, L. A., Waters, E. K., & Brew, B. J. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol. 11, 148 (2011).
65. Vassallo, M et al. Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-Associated neurocognitive disorders? AIDS 28 493-501 2014).
66. Ellis, R. J. et al. Randomized trial of central nervous system-Targeted antiretrovirals for HIV-Associated neurocognitive disorder. Clin. Infect. Dis. 58, 1015-1022 (2014).
67. Cusini, A. et al. Higher CNS penetration-Effectiveness of long-Term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J. Acquir. Immune Defic. Syndr. 62, 28-35 (2013).
68. Ciccarelli, N. et al. Revised central nervous system neuropenetration-Effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. Antivir. Ther. 18, 153-160 (2013).
69. Walker, D. K. et al. Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-Associated lymphoid tissue (GALT). Xenobiotica 38, 1330-1339 (2008).
70. Yilmaz, A., Watson, V., Else, L., & Gisslèn, M. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 23, 2537-2540 (2009).
71. Tiraboschi, J. M., Niubo, J., Curto, J., & Podzamczer, D. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 55, 606-609 (2010).
72. Croteau, D. et al. Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-Type CC chemokine receptor 5-Tropic HIV-1 50% inhibitory concentration. AIDS 26, 890-893 (2012).
73. Garvey, L. et al. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. J. Antimicrob. Chemother. 67, 206-212 (2012).
74. Melica, G. et al. Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms. AIDS 24, 2130-2133 (2010).
75. Kelly, K. M. et al. Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain. AIDS 27, F21-F28 (2013).
76. Roberts, D. J. et al. Effect of acute inflammatory brain injury on accumulation of morphine and morphine 3-And 6-glucuronide in the human brain. Crit. Care Med. 37, 2767-2774 (2009).
77. Reshef, R. et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N. Engl. J. Med. 367, 135-145 (2012).
78. Murai, M. et al. Active participation of CCR5+CD8+ T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J. Clin. Invest. 104, 49-57 (1999).
79. Fleishaker, D. L. et al. Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Res. Ther. 14, R11 (2012).
80. Ben-Nun, A. et al. From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. J. Autoimmun. 54, 33-50 (2014).
81. Sato, W. et al. CCR2+CCR5+ T cells produce matrix metalloproteinase-9 and osteopontin in the pathogenesis of multiple sclerosis. J. Immunol. 189, 5057-5065 (2012).
82. Balashov, K. E., Rottman, J. B., Weiner, H. L., & Hancock, W. W. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1a and IP-10 are expressed in demyelinating brain lesions. Proc. Natl Acad. Sci. USA 96, 6873-6878 (1999).
83. S?rensen, T. L. et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103, 807-815 (1999).
84. Ni, J. et al. The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function. Br. J. Pharmacol. 158, 2046-2056 (2009).
85. Trebst, C. et al. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. J. Pathol. 159, 1701-1710 (2001).
86. Glabinski, A. R., Tani, M., Strieter, R. M., Tuohy, V. K., & Ransohoff, R. M. Synchronous synthesis of a-And β-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am. J. Pathol. 150, 617-630 (1997).
87. Miyagishi, R., Kikuchi, S., Takayama, C., Inoue, Y., & Tashiro, K. Identification of cell types producing RANTES, MIP-1a and MIP-1β in rat experimental autoimmune encephalomyelitis by in situ hybridization. J. Neuroimmunol. 77, 17-26 (1997).
88. Simpson, J. E., Newcombe, J., Cuzner, M. L., & Woodroofe, M. N. Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 84, 238-249 (1998).
89. Boven, L. A., Montagne, L., Nottet, H. S., & De Groot, C. J. Macrophage inflammatory protein-1a (MIP-1a), MIP-1β, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions. Clin. Exp. Immunol. 122, 257-263 (2000).
90. Zheng, H. M., Jiang, Y., Wang, J. R., Gong, X. L., & Guo, B. Y. Mimic peptides bonding specifically with the first and second extracellular loops of the CC chemokine receptor 5 derived from a phage display peptide library are potent inhibitors of experimental autoimmune encephalomyelitis. Inflamm. Res. 60, 759-767 (2011).
91. Glass, W. G. et al. Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J. Immunol. 172, 4018-4025 (2004).
92. Kennedy, K. J., Strieter, R. M., Kunkel, S. L., Lukacs, N. W., & Karpus, W. J. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1a and monocyte chemotactic protein-1. J. Neuroimmunol. 92, 98-108 (1998).
93. Youssef, S. et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J. Immunol. 161, 3870-3879 (1998).
94. Karpus, W. J. et al. An important role for the chemokine macrophage inflammatory protein-1a in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J. Immunol. 155, 5003-5010 (1995).
95. Sapir, Y. et al. A fusion protein encoding the second extracellular domain of CCR5 arrests chemokine-induced cosignaling and effectively suppresses ongoing experimental autoimmune encephalomyelitis. J. Immunol. 185, 2589-2599 (2010).
96. Tran, E. H., Kuziel, W. A., & Owens, T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1a or its CCR5 receptor. Eur. J. Immunol. 30, 1410-1415 (2000).
97. Kantarci, O. H. et al. CCR5?32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J. Neuroimmunol. 169, 137-143 (2005).
98. Silversides, J. A., Heggarty, S. V., McDonnell, G. V., Hawkins, S. A., & Graham, C. A. Influence of CCR5 d32 polymorphism on multiple sclerosis susceptibility and disease course. Mult. Scler. 10, 149-152 (2004).
99. Sellebjerg, F., Madsen, H. O., Jensen, C. V., Jensen, J., & Garred, P. CCR5 ?32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J. Neuroimmunol. 102, 98-106 (2000).
100. van Veen, T. et al. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J. Neuroimmunol. 190, 157-164 (2007).
101. M?ller, M. et al. The chemokine receptor CCR5 ?32 allele in natalizumab-Treated multiple sclerosis. Acta Neurol. Scand. 129, 27-31 (2014).
102. Varadkar, S. et al. Rasmussens encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol. 13, 195-205 (2014).
103. Bien, C. G. et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussens encephalitis. Ann. Neurol. 51, 311-318 (2002).
104. Bauer, J. et al. Astrocytes are a specific immunological target in Rasmussens encephalitis. Ann. Neurol. 62, 67-80 (2007).
105. Schwab, N. et al. CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain 132, 1236-1246 (2009).
106. Kossoff, E. H. et al. Hemispherectomy for intractable unihemispheric epilepsy etiology versus outcome. Neurology 61, 887-890 (2003).
107. Bien, C. G. et al. Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins. Epilepsia 54, 543-550 (2013).
108. Sierra-Madero, J. G. et al. Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial. Lancet HIV 1, e60-E67 (2014).
109. Martin-Blondel, G et al. Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management? AIDS 23 2545-2546 2009).
110. Martin-Blondel, G. et al. Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system in patients infected with HIV. Brain 134, 928-946 (2011).
111. Giacomini, P. S. et al. Maraviroc and JC virus-Associated immune reconstitution inflammatory syndrome. N. Engl. J. Med. 370, 486-488 (2014).
112. Martin-Blondel, G. et al. Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8+ T cells in progressive multifocal leukoencephalopathy-Associated immune reconstitution inflammatory syndrome. Acta Neuropathol. 129, 463-465 (2015).
113. Tan, I. L., McArthur, J. C., Clifford, D. B., Major, E. O., & Nath, A. Immune reconstitution inflammatory syndrome in natalizumab-Associated PML. Neurology 77, 1061-1067 (2011).
114. Vermersch, P. et al. Clinical outcomes of natalizumab-Associated progressive multifocal leukoencephalopathy. Neurology 76, 1697-1704 (2011).
115. Stork, L., Br?ck, W., Bar-Or, A., & Metz, I. High CCR5 expression in natalizumab-Associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc. Acta Neuropathol. 129, 467-468 (2015).
116. Glass, W. G. et al. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202, 1087-1098 (2005).
117. Huffnagle, G. B. et al. Cutting edge: role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J. Immunol. 163, 4642-4646 (1999).
118. Khan, I. A. et al. CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection. PLoS Pathog. 2, e49 (2006).
119. Larena, M., Regner, M., & Lobigs, M. The chemokine receptor CCR5, a therapeutic target for HIV/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitis. PLoS ONE 7, e44834 (2012).
120. Glass, W. G. et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203, 35-40 (2006).
121. Lim, J. K. et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-Analysis of 4 cohorts in the US epidemic. J. Infect. Dis. 197, 262-265 (2008).
122. Lim, J. K. et al. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J. Infect. Dis. 201, 178-185 (2010).
123. Kindberg, E. et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J. Infect. Dis. 197, 266-269 (2008).
124. Mickiene?, A. et al. Polymorphisms in chemokine receptor 5 and Toll-like receptor 3 genes are risk factors for clinical tick-borne encephalitis in the Lithuanian population. PLoS ONE 9, e106798 (2014).
125. Barkhash, A. V., Voevoda, M. I., & Romaschenko, A. G. Association of single nucleotide polymorphism rs3775291 in the coding region of the TLR3 gene with predisposition to tick-borne encephalitis in a Russian population. Antiviral Res. 99, 136-138 (2013).
126. Pulendran, B. et al. Case of yellow fever vaccine-Associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J. Infect. Dis. 198, 500-507 (2008).
127. Nansen, A. et al. The role of CC chemokine receptor 5 in antiviral immunity. Blood 99, 1237-1245 (2002).
128. Zhong, M. X., Kuziel, W. A., Pamer, E. G., & Serbina, N. V. Chemokine receptor 5 is dispensable for innate and adaptive immune responses to Listeria monocytogenes infection. Infect. Immun. 72, 1057-1064 (2004).
129. Silva, A. A. et al. Trypanosoma cruzi-Triggered meningoencephalitis is a CCR1/CCR5-independent inflammatory process. J. Neuroimmunol. 184, 156-163 (2007).
130. Sarfo, B. Y. et al. The cerebral-malaria-Associated expression of RANTES, CCR3 and CCR5 in post-mortem tissue samples. Ann. Trop. Med. Parasitol. 98, 297-303 (2004).
131. Belnoue, E. et al. CCR5 deficiency decreases susceptibility to experimental cerebral malaria. Blood 101, 4253-4259 (2003).
132. McManus, C. M. et al. Chemokine and chemokine-receptor expression in human glial elements: induction by the HIV protein, Tat, and chemokine autoregulation. Am. J. Pathol. 156, 1441-1453 (2000).
133. Albright, A. V. et al. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J. Virol. 73, 205-213 (1999).
134. Spudich, S. S. et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J. Infect. Dis. 191, 890-898 (2005).
135. Shacklett, B. L. et al. Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. J. Infect. Dis. 189, 2202-2212 (2004).
136. Gramegna, P. et al. In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection. PLoS ONE 6, e28499 (2011).
137. Maung, R. et al. CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120. J. Immunol. 193, 1895-1910 (2014).
138. Tiraboschi, J. et al. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-Associated neurocognitive impairment during antiretroviral treatment switch. HIV Med. 16, 388-392 (2015).
139. Ndhlovu, L. C. et al. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-Expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-Associated neurocognitive disease (HAND). J. Neurovirol. 20, 571-582 (2014).
140. Bernal, F. et al. Immunohistochemical analysis of anti-Hu-Associated paraneoplastic encephalomyelitis. Acta Neuropathol. 103, 509-515 (2002).
141. Bien, C. G. et al. Immunopathology of autoantibody-Associated encephalitides: clues for pathogenesis. Brain 135, 1622-1638 (2012).
142. Pignolet, B. S., Gebauer, C. M., & Liblau, R. S. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology 2, e27384 (2013).
143. Saita, Y., Kondo, M., & Shimizu, Y. Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int. Immunopharmacol. 7, 1528-1534 (2007).
144. Sorce, S., Myburgh, R., & Krause, K. H. The chemokine receptor CCR5 in the central nervous system. Prog. Neurobiol. 93, 297-311 (2011).
145. Oppermann, M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell. Signal. 16, 1201-1210 (2004).
146. Gheuens, S., Wüthrich, C., & Koralnik, I. J. Progressive multifocal leukoencephalopathy: why gray and white matter. Annu. Rev. Pathol. 8, 189-215 (2013).
147. Müller, M. et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-Analysis. Lancet Infect. Dis. 10, 251-261 (2010).
148. Martin-Blondel, G. et al. In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection. Neurology 81, 964-970 (2013).
149. Metz, I. et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-Associated progressive multifocal leukoencephalopathy. Acta Neuropathol. 123, 235-245 (2012).
150. Tan, K., Roda, R., Ostrow, L., McArthur, J., & Nath, A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72, 1458-1464 (2009).
151. Clifford, D. B. et al. Natalizumab-Associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 9, 438-446 (2010).
152. Antoniol, C et al. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology 79 2258-2264 2012).